Position in ANAB
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$347,625
+$91,401 QoQ
Shares Held
5,150
-25.7% QoQ
Ownership
0.018%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#130
of 211 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 3%
Shared 0%
None 97%
Common Shares in ANAB Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Hillsdale Investment Management Inc. holds $115,919,445 across 23 Biotechnology names. ANAB ranks #21 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AXSM |
Axsome Therapeutics, Inc.
|
55,000 | $13,462,350 | |
| 2 | BBIO |
BridgeBio Pharma, Inc.
|
169,112 | $12,595,461 | |
| 3 | MRVI |
Maravai Lifesciences Holdings, Inc.
|
1,682,878 | $10,501,158 | |
| 4 | ZYME |
Zymeworks Inc.
|
382,922 | $10,009,581 | |
| 5 | TVTX |
Travere Therapeutics, Inc.
|
167,900 | $9,538,399 | |
| 6 | AUPH |
Aurinia Pharmaceuticals Inc.
|
550,900 | $9,348,773 | |
| 7 | MIRM |
Mirum Pharmaceuticals, Inc.
|
58,630 | $6,863,814 | |
| 8 | ENTA |
Enanta Pharmaceuticals Inc
|
468,000 | $6,823,440 |
All Filings in ANAB
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $347,625 | 5,150 | Shares | Sole | 2026-08-12 | |
| 2026-03-31 | $256,224 | 4,620 | Shares | Sole | 2026-05-04 | |
| No filing history on record for this holder in this stock. | ||||||